Professional Associations & Medical Colleges

The American Psychiatric Association is the national medical specialty society for psychiatry in the United States, with headquarters in Washington, DC and a membership base of psychiatric physicians. It serves psychiatrists and the broader mental health field through official position statements, clinical guidance, journals, and public policy communications. Its core activity is to represent psychiatry in clinical, professional, and policy discussions affecting mental health care. APA has an explicit, cautious stance on psychedelics and empathogens in mental health care. Its 2022 position statement says there is not yet adequate scientific evidence to endorse use outside approved investigational studies, while supporting continued research under strong scientific and regulatory standards. In 2024 APA also submitted comments to FDA on MDMA and in 2026 it publicly welcomed federal investment in psychedelic research while reiterating the need for controlled studies and patient protections.

APSTA, the Association for Psychedelic Science and Therapy Austria, is based in Vienna and describes itself as Austria's leading network for experts in psychedelic research and therapy. It serves medical, psychotherapeutic, psychological, and other professional audiences, with a stated focus on connecting professionals and sharing knowledge, best practices, and experience. Its core activities center on networking, setting guidelines and standards, and education and outreach. APSTA presents itself as a professional association focused on safe, responsible, and evidence-based use of psychedelic substances in therapy and research. Its role appears primarily educational and field-building rather than legislative, with emphasis on ethical practice, public information, and interdisciplinary exchange. Documented examples on its site include supporting research projects, promoting standards for therapy and research, and informing the public about opportunities and risks of psychedelic therapies.

TAIP is an Estonian organization advancing science-based approaches to the use of psychedelics in contemporary therapeutic practices.

The Deutsche Gesellschaft für Psychedelische Forschung und Therapie e.V. is a German professional association based in Germany for physicians, psychologists, and other professionals working in psychedelic research and therapy. Its official site describes it as a specialist society that offers information exchange, supports standards and guidelines, and provides expert advice to professional and policy bodies. Membership is intended for professional practitioners rather than the general public. Its field role is centered on the scientific and clinical introduction of psychedelic-assisted therapies in Germany, with explicit attention to evidence, quality assurance, training, and public communication. The organization also says it supports patient- and family-oriented exchange, advises on certification and approval processes, and helps shape structural conditions for possible clinical use. Current site content highlights a 2026 case under Germany's compassionate-use program for psilocybin in depression, an online members' meeting, and planned contributions to the DGPPN congress.

The Institute of Psychedelic Therapy (IPT) is a UK-based professional training organization offering a comprehensive two-year psychedelic-assisted therapist training program combining weekly online lectures, in-person meetings, and 5-day experiential residential retreats each year. IPT emphasizes slow, relational skill cultivation, robust ethics, and integration of psychedelic work within long-term therapeutic frameworks, with graduates eligible for professional membership.

IDPAT is an Irish organization of doctors, psychotherapists, researchers, and other healthcare workers advocating for psychedelic-assisted therapy in Ireland. Its patient relevance is real, but it is mediated through clinician advocacy, health-system reform, and public reimbursement arguments. The record should therefore be recast as a multi-role stakeholder rather than a straightforward patient organization. Its public language centers on making psychedelic-assisted therapy publicly available and reimbursed, which is highly relevant to access policy and implementation planning.

SIMEPSI, the Italian Society for Psychedelic Medicine, is a nonprofit scientific society based in Italy and focused on psychedelic medicine. Its official materials describe it as a multidisciplinary community of doctors, therapists, researchers, and humanists working to advance research and informed discussion on psychedelic compounds and their therapeutic potential. It appears to operate nationally, with a primary focus on the Italian regulatory and clinical context. SIMEPSI presents itself as a field-building organization rather than a patient service provider. Its stated activities include promoting clinical and basic research, sharing knowledge among experts, supporting training and professional development, and collaborating with institutions on regulation and safe access to psychedelic treatments. It also frames part of its role around public education, risk awareness, and discussion of the social and cultural implications of psychedelic practices.

The Norwegian Association for Psychedelic Science advances psychedelic science as a responsible, interdisciplinary, evidence-based field through knowledge dissemination, professional dialogue, and collaboration between research, clinical practice, and society.

The Psychedelic Medicine Association (PMA) is a professional association that educates and connects healthcare practitioners about the therapeutic use of psychedelic medicines. It also develops clinical practice guidelines, training accreditation, and related infrastructure to support safe integration of psychedelic therapies into mainstream healthcare.

Psychedelic Society Croatia promotes research, education, and ethical application of psychedelics in mental health.

Regional psychiatric college issuing clinical memoranda and implementation guidance on psychedelic-assisted therapy, including MDMA and psilocybin use in regulated psychiatric contexts.

SEMPsi, or the Sociedad Española de Medicina Psicodélica, is a Spanish nonprofit society made up of clinical professionals and mental health researchers. It operates primarily in Spain and appears to serve clinicians, researchers, and other health professionals interested in psychedelic medicine. The group describes its work as promoting therapeutic use and research on psychedelics in an ethical, culturally respectful, evidence-based context. SEMPsi's role is mainly public education, professional formation, and field-building rather than direct patient service delivery. Its manifesto says it produces scientific outreach, training, ethical codes, treatment protocols, and good-practice guidance, and it also aims to advise public and private institutions on clinical use and future legal implementation. Documented current activity includes journal clubs, a university course on psychedelic-assisted psychotherapies, and a parliamentary event in Spain on psychedelic-assisted therapies, as well as coordination with the citizen initiative PsychedeliCare.

The Swiss Medical Association for Psychedelic Therapy (SÄPT) is a Switzerland-based professional medical society founded in 1986, with a German-speaking, interdisciplinary membership that includes psychiatry, psychotherapy, neurology, palliative care, and general medicine. It operates nationally in Switzerland and reports roughly 260 members. Its core activities include improving clinical quality in psychedelic-assisted therapy, supporting professional exchange, and providing theoretical and practical training. SÄPT plays a field-building role in Switzerland’s psychedelic medicine ecosystem by promoting research, developing ethical and treatment standards, and supporting practitioners working under Swiss exceptional authorizations. The organization also engages in policy and health-system advocacy on behalf of its members and participates in the IG PAT network, which issues treatment recommendations for psychedelic-assisted therapy. Current documented initiatives include an education calendar, an academy/training offer, research pages, institutional working groups, and an ombud/service function for people seeking information about psychedelic therapy.